Acinetobacter baumannii: Emergence of a Successful Pathogen

By Anton Y. Peleg, H. Seifert, David L. Paterson. Clinical Microbiology Reviews, 2008

3,455 citations recorded by the source corpus.

Subfields: Endocrinology, Molecular Biology, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/b23d73240f573fd26ff1f56bbc202eddb2af4af7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology

In Molecular Biology

In Molecular Medicine

Citations in the corpus

Acinetobacter, Chryseobacterium, Moraxella, and other Nonfermentative Gram-Negative Rods (2010, background): “baumannii is a continuous source of debate (7, 8).”
Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection (2017, background): “acquiring and maintaining multiple genetic elements encoding antimicrobial resistance 66 determinants (4-6).”
Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production (2010, background): “baumannii strains that are resistant to almost all available antibiotics, including -lactams, fluoroquinolones, tetracyclines, and aminoglycosides (23).”
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges (2016, background): “are particularly prevalent in integrons within multidrug-resistant Acinetobacter strains (247).”
Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options (2017, background): “baumannii has spread to civilian hospitals in part by crossinfection of injured military patients repatriated from war zones (Peleg et al., 2008).”
ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. (2014, neutral): “baumannii has been thoroughly reviewed [79].”
Acinetobacter baumannii (2012, neutral): “While not all Acinetobacters find their habitat in the natural environment, a thorough and systematic study to investigate the natural occurrence of the various Acinetobacter species in the environment has yet to be performed.(5) As a pathogen, A.”
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics (2024, positive): “…complex consists of four species that are difficult to differentiate on a biochemical basis, three of which cause clinical disease ( A. baumannii , Acinetobacter pittii and Acinetobacter nosocomialis ) and one ( Acinetobacter calcoaceticus ) that has a limited pathogenic role 154,155 .”
Acinetobacter baumannii: evolution of a global pathogen. (2014, methodology): “The A. baumannii core genome and pan-genome Comparative genomic approaches have identified a core set of species-specific (Adams et al., 2008; Peleg et al., 2008; Imperi et al., 2011; Farrugia et al., 2013) and genus-specific genes (Vallenet et al., 2008; Chan et al., 2012; Peleg et al., 2012; Zhan…”
The Population Structure of Acinetobacter baumannii: Expanding Multiresistant Clones from an Ancestral Susceptible Genetic Pool (2010, background): “Indeed, this species seems relatively rare in human carriage and almost never found in soil [2].”
Acinetobacter johnsonii and Acinetobacter lwoffii - the emerging fish pathogens (2014, background): “calcoaceticus, are well documented as emerging, opportunistic pathogens in hospitalised humans (9, 17, 18, 24).”
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models (2017, neutral): “All Acinetobacter species, including Acinetobacter baumannii , Acinetobacter calcoaceticus , and Acinetobacter lwoffii , are rare in the healthy human gut microbiome and share genome-wide homology (19, 20), making them indistinguishable by 16S amplicon sequencing.”